Document Detail

Infliximab induces increase in triglyceride levels in psoriatic arthritis patients.
MedLine Citation:
PMID:  21804855     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: To evaluate lipid profile changes after anti-TNF therapy in patients with psoriatic arthritis (PsA).
METHODS: Fifteen PsA patients (eight polyarticular, four oligoarticular, two axial, and one mutilating) under infliximab were included. None had dyslipoproteinemia or previous statin use. Total cholesterol (TC) and its fractions, inflammatory markers, and prednisone use were evaluated.
RESULTS: The comparisons of lipid levels between baseline and after three months (3M) of anti-TNF therapy showed that there was a significant increase in mean triglycerides (117.8 ± 49.7 versus 140.1 ± 64.1 mg/dL, P = 0.028) and VLDL-c (23.6 ± 10.5 versus 28.4 ± 13.7 mg/dL, P = 0.019) levels. In contrast, there were no differences in the mean TC (P = 0.28), LDL-c (P = 0.42), and HDL-c (P = 0.26) levels. Analysis of the frequencies of each lipid alteration at baseline and at 3M were alike (P > 0.05). Positive correlations were found between VLDL-c and CRP (r = 0.647, P = 0.009) and between triglycerides and CRP (r = 0.604, P = 0.017) levels at 3M. ESR reduction was observed after 3M (P = 0.04). Mean prednisone dose remained stable at beginning and at 3M (P = 0.37).
CONCLUSION: This study demonstrated that anti-TNF may increase TG and VLDL-c levels in PsA patients after three months.
Karla R Castro; Nádia E Aikawa; Carla Gonçalves Saad; Júlio C B Moraes; Ana C Medeiros; Licia Maria H Mota; Clovis A A Silva; Eloísa Bonfá; Jozélio F Carvalho
Related Documents :
17143205 - Bilateral subthalamic deep brain stimulation in a patient with parkinson's disease who ...
17408775 - The increase in p-wave dispersion is associated with the duration of disease in patient...
21991485 - Autoantibodies to the β(1)-adrenoceptor from patients with periodontitis as a risk fac...
18972545 - Determination of the longitudinal validity and minimally important difference of the 8-...
23450425 - Association between rates of binocular visual field loss and vision-related quality of ...
18384415 - Idiopathic intracranial hypertension with and without papilloedema in a consecutive ser...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-07-24
Journal Detail:
Title:  Clinical & developmental immunology     Volume:  2011     ISSN:  1740-2530     ISO Abbreviation:  Clin. Dev. Immunol.     Publication Date:  2011  
Date Detail:
Created Date:  2011-08-01     Completed Date:  2011-11-21     Revised Date:  2013-06-28    
Medline Journal Info:
Nlm Unique ID:  101183692     Medline TA:  Clin Dev Immunol     Country:  Egypt    
Other Details:
Languages:  eng     Pagination:  352686     Citation Subset:  IM    
Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / administration & dosage*,  therapeutic use
Antirheumatic Agents / administration & dosage*,  therapeutic use
Arthritis, Psoriatic / blood,  drug therapy*,  pathology
C-Reactive Protein / analysis
Cholesterol, HDL / blood
Cholesterol, LDL / blood
Cholesterol, VLDL / analysis,  blood
Lipid Metabolism / drug effects*
Middle Aged
Prednisone / administration & dosage
Prospective Studies
Triglycerides / blood
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antirheumatic Agents; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Cholesterol, VLDL; 0/Triglycerides; 0/infliximab; 53-03-2/Prednisone; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Management Recommendations for Metabolic Complications Associated with Second Generation Antipsychot...
Next Document:  Assessing the effects of acupuncture by comparing needling the hegu acupoint and needling nearby non...